You are here

P&T August 2016

Features

In response to the alarming rate of opioid overdose deaths in the U.S., the President, Congress, and federal agencies are making efforts to reduce the number of fatalities.

Part 2: Adult Vaccinations

Despite annual recommendations, American adults remain inadequately vaccinated. The author outlines how compliance may be improved through health care professional interventions, as well as government and community-based programs.

As in the U.S., there is no unified national formulary in Saudi Arabia, so individual institutions must develop their own medication lists. A Saudi health system’s strategy for maintaining formulary safety, efficacy, and cost-effectiveness is described.

Meeting Highlights

We present EULAR sessions on the latest treatments for rheumatic disease with an infliximab biosimilar, certolizumab pegol, secukinumab, and bimekizumab.

Meeting Highlights

We report on significant developments in diabetes presented at ADA’s Scientific Sessions.

Pipeline Plus

Tyrosine kinase inhibitors (TKIs) are leading systemic therapies for the treatment of renal cell carcinoma. However, programmed death-1 inhibitors, promising new agents in development, may surpass TKIs as the standard of care in the future.

Departments

Medication Errors

Inadvertent intrathecal vincristine administration causes fatalities

Prescription: Washington

Recent FDA compounding guidances raise hackles

New Drugs/Drug News

Approvals, new indications, regulatory activities, and more

Venetoclax (Venclexta) for chronic lymphocytic leukemia; riboflavin 5′-phosphate solutions (Photrexa Viscous and Photrexa) for progressive keratoconus; and pimavanserin (Nuplazid) for Parkinson’s disease psychosis

Drug Forecast

Ceftazidime-avibactam (Avycaz) for the treatment of complicated infections

Meeting Highlights

We present EULAR sessions on the latest treatments for rheumatic disease with an infliximab biosimilar, certolizumab pegol, secukinumab, and bimekizumab. We also report on significant developments in diabetes presented at ADA’s Scientific Sessions.